Aspreva says mycophenolate mofetil approved for treatment of lupus nephritis in Malaysia

By Elaine Rigoli

Tampa, Fla., July 19 - Aspreva Pharmaceuticals Corp. said the Drug Control Authority in Malaysia has granted approval to include lupus nephritis as an additional indication for mycophenolate mofetil (MMF) in the induction and maintenance treatment of lupus nephritis (used concomitantly with corticosteroids).

Malaysia is the first country to have regulatory approval of MMF in any autoimmune disease.

Aspreva is conducting a global phase 3 study to assess the efficacy and safety of MMF in inducing response and maintaining remission in patients with lupus nephritis.

Aspreva is a pharmaceutical company based in Victoria, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.